Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

In April 2024, the ODAC approved minimal residual disease as a regulatory endpoint for multiple myeloma (MM), expediting drug approvals. This study revealed financial conflicts of interest among 60% of US-based physician speakers at the meeting, with over $792,200 in payments from MM companies, raising concerns about regulatory integrity.